ArticleFrontiers in bioinformatics2025
BC-predict: mining of signal biomarkers and production of models for early-stage breast cancer subtyping and prognosis.
Article in Frontiers in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Simultaneous Preoperative Prediction of Locally Advanced Breast Cancer, DCIS Component, and Multifocality Using Structured Mammographic Features and Gradient-Boosting Machine Learning.Diagnostics (Basel, Switzerland) · 2026Article
- BreastSubtypeR: a unified R/Bioconductor package for intrinsic molecular subtyping in breast cancer research.NAR genomics and bioinformatics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Disease heterogeneity is the hallmark of breast cancer, which is the most common female malignancy. With a disturbing increase in mortality and disease burden, there remains a need for effective early-stage theragnostic and prognostic biomarkers. In this work, we improved on BrcaDx (https://apalania.shinyapps.io/brcadx/) for cancer vs control screening and examined a cluster of adjoining learning problems in breast cancer heterogeneity: (i) identification of metastatic cancers; (ii) molecular subtyping (TNBC, HER2, or luminal); and (iii) histological subtyping (invasive ductal or invasive lobular). Methods: We analyzed the transcriptomic profiles of breast cancer patients from public-domain databases such as the TCGA using stage-encoded problem-specific statistical models of gene expression and unveiled stage-salient and progression-significant genes. Using a consensus approach, we identified potential machine learning features, and considered six model classes for each learning problem, with hyperparameter optimization on a training dataset and evaluation on a holdout test dataset. A nested approach enabled us to identify the best model class for each learning problem. Results: External validation of the best models yielded balanced accuracies of 97.42% for cancer vs normal; 88.22% for metastatic v/s non metastatic; 88.79% for ternary molecular subtyping; and ensemble accuracy of 94.23% for histological subtyping. The model for molecular subtyping was validated on a 26-sample TNBC-only out-of-distribution cohort, yielding 25 correct predictions. We performed a late integration of multi-omics datasets by validating the feature space used in each problem with miRNA profiles, methylation profiles, and commercial breast cancer panels. Discussion: Pending prospective studies, we have translated the models into BC-Predict that forks the best models developed for each problem in a unified interface and provides a complete readout for input instances of expression data, including uncertainty estimates. BC-Predict is freely available for non-commercial purposes at: https://apalania.shinyapps.io/BC-Predict.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.